Loading stock data…
Repligen Corporation (RGEN)
$168.53+0.93 (+0.55%)
After Hours$168.53+0.00 (+0.00%)· Last close Sep 8
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Repligen Corporation in the Healthcare sector is trading at $168.53 with a market capitalization of $9.5B. Wall Street consensus targets $187.70 (20 analysts), implying a +11.4% move over the next 12 months. The stock is currently 11% below its 52-week high of $188.73, remaining 18.6% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $204.13M↑ | $194.25M↓ | $197.91M↑ | $188.81M↑ | $182.37M |
| Gross Profit | $110.04M↑ | $108.28M↑ | $103.83M↑ | $100.52M↑ | $93.00M |
| Operating Income | $19.00M↑ | $17.29M↑ | $16.35M↑ | $12.68M↑ | $8.12M |
| Net Income | $5.01M↓ | $8.33M↓ | $13.29M↓ | $14.91M↑ | $14.87M |
Peer Comparison
JNJUNHPFE
Fundamentals
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatogr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.51B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
227.74
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.97%
Volume
Today's trading volume
779,439
Recent News
Repligen (RGEN) Stock Looks Near Fair Value After Recent Rebound
Repligen stock has delivered a strong 1 year gain, yet the broader valuation checks and recent history raise questions about how much upside is left. The intrinsic value estimate from a Discounted Cash Flow (DCF) view is close to the current share price, while market-based multiples lean more expensive. Over 5 years, Repligen shares have declined about 42%, which points to a difficult longer term journey despite a healthier recent rebound. The valuation story now hinges on whether Repligen...
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QURE Submits Application for Gene Therapy for Huntington's Disease
QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.